Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.0021 USD
Change Today 0.00 / 0.00%
Volume 45.0M
ADMD On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

advanced medical isotope cor (ADMD) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/29/14 - $0.04
52 Week Low
12/9/14 - $0.0001
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

advanced medical isotope cor (ADMD) Related Businessweek News

No Related Businessweek News Found

advanced medical isotope cor (ADMD) Details

Advanced Medical Isotope Corporation develops brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. The company focus is on development of brachytherapy cancer product, yttrium-90 RadioGel; and yttrium-90 brachytherapy products. It is also engaged in the development of other medical isotopes for therapeutic and diagnostic purposes; operation of a nuclear accelerator; and the sale of third party isotopes. The company’s customers for stable isotopes include a range of hospitals, universities, research centers, and national laboratories, as well as academic and government institutions in the United States and internationally. Advanced Medical Isotope Corporation is based in Kennewick, Washington.

advanced medical isotope cor (ADMD) Top Compensated Officers

Co-Founder, Chairman and Chief Executive Offi...
Total Annual Compensation: $305.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $221.5K
Compensation as of Fiscal Year 2013.

advanced medical isotope cor (ADMD) Key Developments

Advanced Medical Isotope Corporation announced delayed annual 10-K filing

On 03/31/2015, Advanced Medical Isotope Corporation announced that they will be unable to file their next 10-K by the deadline required by the SEC.

Advanced Medical Isotope Corporation Files a 'De Novo' Submission with the Food and Drug Administration for Marketing Clearance for its Patented Y-90 RadioGel(TM)

Advanced Medical Isotope Corporation announced that it has filed a de novo submission with the Food and Drug Administration ("FDA") for marketing clearance for its patented Y-90 RadioGel(TM) device pursuant to Section 513(f)(2) of the U.S. Food, Drug and Cosmetic Act. In February 2014, the FDA rejected the Company's request for marketing clearance for the same device under Section 510(k) of the Act. The FDA determined that the device was not substantially equivalent, concluding that the device is classified by statute as a Class III medical device, unless the device is reclassified. By filing the de novo submission, the company is seeking reclassification of the product to Class II. The FDA has 120 days in which to make a decision, though the period will be extended for any time AMIC requires to respond to FDA requests for additional information. If the de novo submission is granted, the device may be immediately marketed in the United States, though the company would have to secure funding and commercial arrangements before marketing could commence. If the de novo submission is declined, the company will explore steps toward seeking approval for the device as a Class III medical device. Generally, the time period and cost of seeking approval as a Class III medical device is materially greater than the time period and cost of seeking approval as a Class II medical device.

Advanced Medical Isotope Corporation Proposes Amendment to Article of the Certificate of Incorporation

Advanced Medical Isotope Corporation proposed an amendment of Article IV of the Certificate of Incorporation to increase the number of authorized shares of Common Stock from 500,000,000 shares to 2,000,000,000 shares to the Special Meeting of Stockholders will be held on October 28, 2014.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMD:US $0.00 USD 0.00

ADMD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMD.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADMD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 68.3x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADVANCED MEDICAL ISOTOPE COR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at